ABSTRACT
Bispecific antibodies (BsAbs) are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens. Several bispecific modalities have been developed, but their utility is limited due to problems with stability and manufacturing complexity. Here we report a versatile technology, based on a scaffold antibody and pharmacophore peptide heterodimers, that enables rapid generation and chemical optimization of bispecific antibodies, which are termed bispecific CovX-Bodies. Two different peptides are joined together using a branched azetidinone linker and fused to the scaffold antibody under mild conditions in a site-specific manner. Whereas the pharmacophores are responsible for functional activities, the antibody scaffold imparts long half-life and Ig-like distribution. The pharmacophores can be chemically optimized or replaced with other pharmacophores to generate optimized or unique bispecific antibodies. As a prototype, we developed a bispecific antibody that binds both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2) simultaneously, inhibits their function, shows efficacy in tumor xenograft studies, and greatly augments the antitumor effects of standard chemotherapy. This unique antiangiogenic bispecific antibody is in phase-1 clinical trials.
Subject(s)
Angiopoietin-2/immunology , Antibodies, Bispecific/immunology , Antibodies, Bispecific/pharmacology , Vascular Endothelial Growth Factor A/immunology , Amino Acid Sequence , Angiopoietin-2/chemistry , Angiopoietin-2/metabolism , Animals , Antibodies, Bispecific/metabolism , Antibody Specificity , Antineoplastic Agents/immunology , Antineoplastic Agents/pharmacology , Azetidines/chemistry , Cell Line, Tumor , Enzyme-Linked Immunosorbent Assay , Humans , Immunologic Factors/immunology , Immunologic Factors/metabolism , Immunologic Factors/pharmacokinetics , Macaca fascicularis , Male , Mice , Mice, Nude , Molecular Sequence Data , Neoplasms/drug therapy , Neoplasms/immunology , Neoplasms/pathology , Protein Binding , Rats , Rats, Sprague-Dawley , Surface Plasmon Resonance , Tumor Burden/drug effects , Vascular Endothelial Growth Factor A/chemistry , Vascular Endothelial Growth Factor A/metabolism , Vascular Endothelial Growth Factor Receptor-2/metabolism , Xenograft Model Antitumor AssaysABSTRACT
IL-17A is a pro-inflammatory cytokine that has been implicated in autoimmune and inflammatory diseases. Monoclonal antibodies inhibiting IL-17A signaling have demonstrated remarkable efficacy, but an oral therapy is still lacking. A high affinity IL-17A peptide antagonist (HAP) of 15 residues was identified through phage-display screening followed by saturation mutagenesis optimization and amino acid substitutions. HAP binds specifically to IL-17A and inhibits the interaction of the cytokine with its receptor, IL-17RA. Tested in primary human cells, HAP blocked the production of multiple inflammatory cytokines. Crystal structure studies revealed that two HAP molecules bind to one IL-17A dimer symmetrically. The N-terminal portions of HAP form a ß-strand that inserts between two IL-17A monomers while the C-terminal section forms an α helix that directly blocks IL-17RA from binding to the same region of IL-17A. This mode of inhibition suggests opportunities for developing peptide antagonists against this challenging target.
Subject(s)
Enzyme Inhibitors/metabolism , Interleukin-17/antagonists & inhibitors , Peptides/metabolism , Receptors, Interleukin-17/metabolism , Amino Acid Substitution , Cells, Cultured , Crystallography, X-Ray , Enzyme Inhibitors/isolation & purification , Humans , Interleukin-17/chemistry , Mass Screening , Models, Molecular , Mutagenesis , Peptide Library , Peptides/chemistry , Peptides/isolation & purification , Protein Binding , Protein ConformationABSTRACT
Novel phage-derived peptides are the first reported molecules specifically targeting human placental growth factor 1 (PlGF-1). Phage data enabled peptide modifications that decreased IC(50) values in PlGF-1/VEGFR-1 competition ELISA from 100 to 1 µM. Peptides exhibiting enhanced potency were bioconjugated to the CovX antibody scaffold 1 (CVX-2000), generating bivalent CovX-Bodies with 2 nM K(D) against PlGF-1. In vitro and in vivo peptide cleavage mapping studies enabled the identification of proteolytic hotspots that were subsequently chemically modified. These changes decreased IC(50) to 0.4 nM and increased compound stability from 5% remaining at 6 h after injection to 35% remaining at 24 h with a ß phase half-life of 75 h in mice. In cynomolgus monkey, a 78 h ß half-life was observed for lead compound 2. The pharmacological properties of 2 are currently being explored.